Rubius Therapeutics Operating Income

Rubius Therapeutics (RUBY) currently reports a operating income of $-160M as of December 2022. That compares with $-190M in the prior-year period — up 20.1% year over year. Use the charts on this page to explore Rubius Therapeutics's operating income history and peer comparisons.

Rubius Therapeutics's operating income increased from $-190M to $-160M — a 20.1% year-over-year increase (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Rubius Therapeutics reported $-160M in operating income as of December 2022. That compares with $-190M in the prior-year period — up 20.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-160M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Rubius Therapeutics, and consider following RUBY for alerts when major investors trade the stock.

Rubius Therapeutics is classified in the Healthcare sector. On operating income, it currently shows $-160M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RUBY with unrelated industries.